Patents by Inventor Jade FOGHA

Jade FOGHA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RORgamma modulators and uses thereof
    Patent number: 11974997
    Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: May 7, 2024
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • RORGAMMA MODULATORS AND USES THEREOF
    Publication number: 20220133716
    Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Application
    Filed: October 5, 2021
    Publication date: May 5, 2022
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • RORgamma modulators and uses thereof
    Patent number: 11160801
    Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 2, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • Rorgamma modulators and uses thereof
    Patent number: 11077115
    Abstract: The present invention provides novel compounds of formula (Ia) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: August 3, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • RORgamma modulators and uses thereof
    Patent number: 10987351
    Abstract: The present invention provides novel compounds of formula (Ia) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: April 27, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • RORGAMMA MODULATORS AND USES THEREOF
    Publication number: 20200000815
    Abstract: The present invention provides novel compounds of formula (Ia) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Application
    Filed: January 29, 2018
    Publication date: January 2, 2020
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • RORGAMMA MODULATORS AND USES THEREOF
    Publication number: 20190388414
    Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Application
    Filed: January 29, 2018
    Publication date: December 26, 2019
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • RORGAMMA MODULATORS AND USES THEREOF
    Publication number: 20190358223
    Abstract: The present invention provides novel compounds of formula (Ia) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Application
    Filed: January 29, 2018
    Publication date: November 28, 2019
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • Mcl-1 modulating compounds for cancer treatment
    Patent number: 10307410
    Abstract: The invention relates to compounds of formula (I), and to their therapeutic use in the treatment of cancer: Wherein Y1, Y2, Ar1, Ar2, R1, R2, i, j, k, l are as defined in claim 1.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: June 4, 2019
    Assignees: CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE, UNIVERSITE DE CAEN BASSE-NORMANDIE, INSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEAU
    Inventors: Laurent Poulain, Anne-Sophie Voisin-Chiret, Jana Sopkova-de Oliveira Santos, Ronan Bureau, Grégory Burzicki, Marcella De Giorgi, Serge Perato, Jade Fogha, Sylvain Rault, Philippe Juin, Fabien Gautier
  • MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT
    Publication number: 20170071921
    Abstract: The invention relates to compounds of formula (I), and to their therapeutic use in the treatment of cancer: Wherein Y1, Y2, Ar1, Ar2, R1, R2, i, j, k, l are as defined in claim 1.
    Type: Application
    Filed: March 3, 2015
    Publication date: March 16, 2017
    Applicants: CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE, UNIVERSITE DE CAEN BASSE-NORMANDIE, INSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEAU
    Inventors: Laurent POULAIN, Anne-Sophie VOISIN-CHIRET, Jana SOPKOVA-DE OLIVEIRA SANTOS, Ronan BUREAU, Grégory BURZICKI, Marcella DE GIORGI, Serge PERATO, Jade FOGHA, Sylvain RAULT, Philippe JUIN, Fabien GAUTIER